NICE rejects thyroid cancer drugs
It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and Sanofi Genzyme’s Caprelsa via the Cancer Drugs Fund, after cost-regulators turned down funding for their use.
Read More
Tag: Elixis
- Immunotherapy combination shows unprecedented results in multiple myeloma
- Modus Therapeutics advances sevuparin study in chronic kidney disease with anemia
- Five-year study confirms durable efficacy of etranacogene dezaparvovec
- Enterprise Therapeutics publishes results of phase 1 study of ETD001
- Rybrevant accepted in Scotland for lung cancer treatment
